Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Acknowledged signatures of matrix metalloproteinases in
Takayasu's arteritis
Gang Wu
Wuhan General Hospital of Guangzhou Command

Nitin Mahajan
Washington University School of Medicine in St. Louis

Veena Dhawan
Postgraduate Institute of Medical Education and Research

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Wu, Gang; Mahajan, Nitin; and Dhawan, Veena, ,"Acknowledged signatures of matrix metalloproteinases in
Takayasu's arteritis." Journal of Nanomaterials. 2014,. 1-8. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/3273

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 827105, 8 pages
http://dx.doi.org/10.1155/2014/827105

Review Article
Acknowledged Signatures of Matrix Metalloproteinases in
Takayasu’s Arteritis
Gang Wu,1 Nitin Mahajan,2,3 and Veena Dhawan2
1

Department of Orthopedics, Wuhan General Hospital of Guangzhou Command, 627 Wuluo Road, Wuhan, Hubei 430070, China
Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER),
Chandigarh 160036, India
3
Division of Molecular Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
2

Correspondence should be addressed to Gang Wu; wugang19830321@gmail.com and Nitin Mahajan; dr.nitin20@yahoo.com
Received 17 June 2014; Revised 12 August 2014; Accepted 12 August 2014; Published 3 September 2014
Academic Editor: Fabrizio Montecucco
Copyright © 2014 Gang Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Takayasu’s arteritis (TA) was reported as an eye disease in the year 1905 and later was confirmed as a vasculitis. Since then, the
etiology of the disease remains unknown; however, characteristic clinical features suggest multiple causative factors. Recent progress
in vascular biology and other disciplines enlightens the pathophysiology of TA and demonstrated induction of various nonspecific
inflammatory symptoms and destruction of the arterial wall, which leads to aneurysms and rupture of the affected arteries. Matrix
metalloproteinases (MMPs) as an enzyme family have well-established roles in several vascular pathologies including intima
formation, atherosclerosiss and aneurysms. MMPs have been proposed to be one of the molecules with a potential of having dual
role in the course of TA, first as an active participant in pathophysiology and secondly as a diagnostic biomarker for TA disease.
The desire to improve our understanding of the importance of MMPs and their endogenous inhibitors (TIMPs) in TA disease
and for the development of therapeutic agents has inspired basic and clinical scientists for over a decade. In the present paper, we
summarized the scientific rationale which highlights the signatures of matrix metalloproteinases and their endogenous inhibitors
in pathophysiology as well as their being a potential candidate as biomarker for Takayasu’s arteritis.

1. Introduction
Takayasu’s arteritis is a chronic vasculitis that affects large
vessels and its main branches [1–3]. Mikito Takayasu, a
Japanese ophthalmologist reported a case of a young female
whose eyes exhibited “coronary anastomosis,” arteriovenous
anastomosis around the papilla in 1905, which is the first
description of this disease in the literature [4, 5]. Several
cases were reported in Japan after this, including a report
in 1939 by Yasuzo Shinmi who used the term “Takayasu’s
arteritis” for the first time [6]. It was later in 1948 when
Schimizo and Sano recognized the clinical triad of absent
radial pulses, hypertensive carotid sinus, and ocular fundal
changes [7]. Clinically varied ischemic symptoms due to
stenotic lesions or thrombus formation, including blindness,
cataract, and/or retinal haemorrhage, pulselessness, aortic
regurgitation, and/or congestive heart failure due to dilatation of the ascending aorta have been reported worldwide.

Aneurysms and/or dissecting aneurysm or rupture of the
involved arteries due to the destruction of the media of
the arterial wall has been commonly reported in the acute
condition of the disease [1, 8–12]. Though, a number of
studies, experimental and clinical, have been conducted
worldwide, the pathophysiology of the disease still remains
enigmatic. Factors like infectious agents, autoimmunity, and
genetic factors are considered to play a major role in the
physiopathology of this disease. Clinical manifestations of TA
are highly variable and depend on the stage of disease and
distribution of vascular lesions [1, 3]. Significant geographical
variations are also noted in the frequency of major clinical
features in subjects with TA [7, 13, 14].
Recent epidemiological data are lacking; however, previous studies demonstrated a major prevalence of TA in Asian
and Central and South American countries like Japan, India,
China, Korea, Thailand, Peru, Israel, Brazil, and Mexico [1,
15–18]. Studies from USA and Sweden estimated incidence
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rates to be 2.6 and 1.2 cases per million populations per
year [13]. TA has been reported to occur predominantly in
the females as compared to males [1, 15]. The female and
male ratio shows significant variation among different ethnic
groups being 8–24 : 1 among Japanese patients and 6 : 1 in
Korean [19], 2.1 : 1 in Indian [16], 1.2 : 1 in Israeli, 2.15 : 1 in Thai
patients [20] and 8.4 : 1 among the Turkish patients [21] and
6 : 1 in Brazilian [22] and 6.9 : 1 in Mexican patients [23].
Histopathologically TA is characterized as a “panarteritis,” involving all the layers of the arterial wall [1, 2, 24].
In TA, the earliest change appears to be a granulomatous
inflammation in the adventitia and outer layers of the affected
arteries, followed by gradual progression to a panarteritis
with inflammatory mononuclear cell infiltration. The normal
architecture of the vessel is disrupted, resulting from histologically characterized degeneration of the elastic lamella in
the media of affected elastic arteries. The process eventually
produces intimal thickening and scarring and aneurysms
form in the weakened arterial walls, particularly when the
aorta itself is involved. In this process, proteases (majorly
MMPs) secreted from infiltrated cells as well as resident
vascular cells come into the play and virtue of their inevitable
property to degrade extracellular matrix (ECM) leads to
vascular remodeling [2, 24, 25]. Matrix metalloproteinases
(MMPs) and their endogenous inhibitors (TIMPs) have been
studied to explore their importance in pathophysiology as
well as their being a candidate biomarker for Takayasu’s
arteritis (TA). In the present paper we summarized the
scientific rationale which highlights the signatures of MMPTIMP axis in Takayasu’s arteritis.

2. Matrix Metalloproteinases
Matrix metalloproteinases are a family of more than 20
structurally related, zinc-containing enzymes that degrade
the extracellular matrix (ECM) and connective tissue proteins. Remodeling of ECM components by MMPs affects
proliferation, migration, and apoptosis of vascular cells [26,
27]. Under normal physiological conditions these MMPs
are under tight control of their endogenous inhibitors, that
is, tissue inhibitors of matrix metalloproteinases (TIMPs).
An imbalance between MMPs and TIMPs could thus cause
increase in the activity of MMPs and, therefore, lead to
pathological changes in the vessel wall structure associated
with vascular disease [25–28].
MMPs typically consist of four domains, that is, propeptide domain (∼80 AA long), catalytic domain (∼170 AA long),
hinge region (of variable length), and hemopexin domain
(∼200 AA long) (Figure 1). Proteinases assigned to the MMP
family have three molecular signatures. (i) Sequence homology with collagenase-1 (MMP-1). (ii) Cysteine switch motif
PRCGXPD in the prodomain that maintains MMPs in their
pro-MMP zymogen form. The conserved cysteine chelates
the active zinc site. MMP-23 has a unique cysteine-rich region
and an immunoglobulin-like domain in place of hemopexin
domain. (iii) Zinc-binding motif bound by 3 histidine
molecules with the conserved sequence HEXGHXXGXXH
located in the catalytic domain [27–30]. In normal physiological vascular remodelling, the activities of MMPs are
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tightly regulated at the transcription level, activation of
their proform or zymogens, their interaction with specific
ECM components, and inhibition by endogenous inhibitors.
Activation of proforms of MMPs involves detaching of the
hemopexin domain and requires the action of other MMPs
or other classes of proteinases [29, 31].
Currently, 26 members of the MMP family have been
identified in vertebrates out of which 23 of them have been
found in humans [27–29, 31]. MMPs are divided into the
following six groups (Table 1). (i) Collagenases, a group of
MMPs, include MMP-1, MMP-8, MMP-13, and MMP-18. (ii)
Gelatinases include gelatinase-A (MMP-2) and gelatinase-B
(MMP-9), mainly digest denatured collagens (gelatins). (iii)
Stromelysins include MMP-3 and MMP-10 and MMP-11. (iv)
Matrilysins include matrilysin-1 (MMP-7) and matrilysin2 (MMP-26, endometase). This group of MMPs lacks the
hemopexin domain. (v) Membrane-type MMPs (MT-MMPs)
include the type-I transmembrane proteins MT1-, MT2-,
MT3-, and MT4-MMP (MMP-14, MMP-15, MMP-16, and
MMP-24) and the glycosylphosphatidylinositol- (GPI-)
anchored proteins MT5- and MT6-MMP (MMP-17 and
MMP-25). MT1-MMP can digest type-I, -II, and -III collagen
and other components of ECM. These can also activate proMMP to MMP. (vi) Other MMPs include MMP-12, MMP-19,
MMP-20, MMP-22, MMP-23, and MMP-28 [27–29, 31].
Tissue inhibitors of matrix metalloproteinases (TIMPs)
(21–29 KDa) are specific endogenous inhibitors that bind
to MMPs in a 1 : 1 stoichiometry and reversibly inhibit the
proteolyitic activity of MMPs. Four TIMPs (TIMP1–4) have
been identified so far, and their expression is regulated during
development and tissue remodeling. Structurally TIMPs are
40% identical [32] and have an N-terminal domain (125 AA)
and C-terminal domain (65 AA), each containing 3 conserved disulfide bonds. The N-terminal domain folds as a
separate unit and is capable of inhibiting MMPs [30, 33–
35]. Disulfide bonds at conserved cysteine residues maintain
the six loop structures. The inhibitory function of TIMPs
occurs through the interaction between Zn2+ of the MMPs
with the N-terminal cysteine residues of the TIMPs [32].
TIMP1, TIMP2, and TIMP4 are known to be localised
extracellularly in soluble form, while TIMP3 is reported to
be tightly attached to extracellular matrix [32, 36]. However,
recent study demonstrated that TIMP3 could also be present
in the extracellular space in soluble form [37]. Despite the
overlap among TIMPs in their inhibitory functions, each
TIMP possesses unique property and inhibits the activity of
MMPs with different sensitivity and specificity.

3. MMP-TIMP Axis in Pathophysiology of
Takayasu’s Arteritis
Matrix remodeling is a complex process and is controlled
by an intricate network of cells and matrix interactions.
Adventitial inflammation is the predominant feature in many
forms of arteritis where inflammatory cells cluster in the
adventitial space surrounding the afflicted artery [38, 39].
There is growing evidence that MMPs are involved in all
stages of the atherosclerotic disease, from the initial lesion
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Basic structure of MMPs
(Collagenases (MMP-1, MMP-8,
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Figure 1: Structure of matrix metalloproteinases (MMPs). MMPs contain four domains, that is, prodomain, catalytic domain, hinge region,
and hemopexin domain; however, each MMP has a slight difference in its subunit organization. Catalytic domain has Zn2+ binding site.
Matrilysins lack hinge region and hemopexin domain. Gelatinases (MMP-2 and MMP-9) contain three repeats of a fibronectin-like motif that
bind gelatin. MMPs contain a specific recognition motif for intracellular furin-like serine proteinases (Fu) that allows intracellular activation
by these proteinases. Membrane-type MMPs contain a transmembrane domain or a glycosylphosphatidylinositol anchor. MMP-23 has a
unique cysteine-rich region and an immunoglobulin-like domain in the place of hemopexin domain.

to plaque rupture. Increased levels of cytokines within that
microenvironment might induce production of MMPs from
various resident and inflammatory cells, which results in
the destruction of elastic fibers in the arterial media [40,
41]. Despite the evidence, the role of adventitia in vascular
lesion formation and in the pathogenesis of Takayasu’s
arteritis has been controversial [24, 42, 43]. In an important
in vitro study, Mahajan et al. demonstrated that a direct
contact between activated T-lymphocytes (isolated from TA
subjects) and HT1080 fibroblast leads to enhanced expression
of MMPs. Subcellular fractionation studies with T cells
isolated from TA subjects pointed out the presence of some
unidentified antigenic moiety in membrane fraction which
is responsible for the enhanced expression of MMPs by
HT1080 cells [44]. Therefore, interaction of different cells in
the adventitial setting generates a microenvironment which
channelizes cells to invade the media and intima through
adventitia due to augmented MMP expression. Inhibiting
the direct interaction of these cells can be a potential target

for developing novel biological strategies for modulating the
ECM turnover.
Finding enhanced transcriptional expression of MMPs in
TA subjects as compared to normal healthy controls, Mahajan
et al. emphasized the fact that extracellular matrix remodeling is activated in TA disease, thus making these subjects
highly vulnerable to atherosclerosis and development of its
related manifestations and aneurysms [44]. In corroboration,
increased serum levels of MMPs and gelatinolytic activities of
MMPs have been demonstrated in TA subjects [14, 17, 44–
47]. Various cytokines and chemokines, like interleukin-6
(IL-6), regulated on activation normal T cell expressed and
secreted (RANTES), and monocytic chemotactic protein-1
(MCP-1), are reported to increase in patients with TA and
therefore could possibly accelerate the production of MMPs
by inflammatory [16, 47, 48].
The potential role of reactive oxygen (ROS) and nitrogen
(RNS) species to influence ECM remodeling though activation of MMPs is well versed in different vascular disease
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Table 1: Summary of the various MMPs and TIMPs and alterations in their levels in subjects with Takayasu’s arteritis.

Subgroup

Observations

MMPs/TIMPs

N.S

[17]

TA > C, A > R (mRNA)

[44]

MMP-8 (collagenase-2)

—

—

MMP-13 (collagenase-3)

—

—

MMP-18 (collagenase-4)

—

—

MMP-1 (collagenase-1)
Collagenases

Reference

MMP-2 (gelatinase-A)

Gelatinases
MMP-9 (gelatinase-B)

N.S

[53]

TA > C, A > R (Activity)

[14]

A>C

[46]

TA > C

[17]

TA > C; A > R

[47]

A>R>C

[53]

TA > C, A > R (mRNA)

[44]

TA > C, A > R (Activity)

MMP-3 (stromelysin 1)
Stromelysins

Matrilysins
Membrane-type MMPs
Other MMPs

A>C

[46]

N.S

[17]

TA > C

[47]

N.S

[53]

TA > C, A > R (mRNA)

[44]

MMP-10 (stromelysin 2)

—

—

MMP-11 (stromelysin 3)

—

—

MMP-7 (matrilysin-1)

—

—

MMP-26 (matrilysin-2)
MMP-14, MMP-15, MMP-16, MMP-17, MMP-23,
MMP-24, and MMP-25

—

—

—

—

MMP-12, MMP-19, MMP-20, MMP-22, and MMP-28
TIMP1

TIMPs

—

—

C>A

[46]

TA > C, R > C

[17]

C > TA

[47]

TA > C, A versus R = N.S (mRNA)

[44]

TIMP2

—

TIMP3

—

TIMP4

—

TA: total TA population; A: active; R: remission; C: controls; N.S: not significant.

settings [29]. A positive correlation of increased oxidative
stress with levels of MMPs in TA has been demonstrated
previously [14]. A negative association of soluble receptor for
advanced glycation end products (sRAGE; an antiatherogenic
molecule) with MMPs in TA has also been documented [17]
and, therefore, provides another evidence for the importance
of MMPs in pathophysiology of TA.

4. MMP-TIMP Axis as Biomarker in
Takayasu’s Arteritis
In the natural course of TA, patients experience cycles of
active and remission phases that reflect the different inflammatory states of the arterial lesions [2]. Monitoring of disease
is very important to check the activity as well as to choose

the appropriate therapeutic strategy. Though, prognosis and
vascular complications of TA are improving day by day, still
development of a single or multiple biomarker approach is
desirable. Matrix metalloproteinase has been studied widely
in various diseases as a potential disease biomarker. As stated
earlier, TA is associated with a significantly increased risk and
a higher prevalence of atherosclerosis. Cardiovascular complications including cardiac failure, pulmonary hypertension,
cerebrovascular incident, myocardial infarction (MI), and
ruptured aortic aneurysm are the major causes of morbidity
and mortality [1, 2, 9, 18]. Increased levels of MMPs have been
reported in various vascular and vasculitic pathophysiologies
like giant cell arteritis [49], Kawasaki disease [50], atherosclerosis and related complications [31, 51], Henoch Schonlein
purpura (HSP) subjects [52], and so forth.

BioMed Research International
Matsuyama et al. have demonstrated that MMP-2 levels
were higher in patients with TA than in controls, but no
correlation was found between serum MMP-2 and disease
activity score [46]. Based on their results these authors
concluded that MMP-2 is a helpful biomarker in the diagnosis
of TA but not for determining the phase of the disease.
On the contrary, recently Ishihara et al. did not find any
significant difference in the levels of MMP-2 when compared
between TA subjects and controls in Japanese population
[53].
MMP-3 levels were also reported in TA subjects in
different studies, though contrary. Levels of MMP-3 were
found to be significantly high in TA subjects compared to
controls [46, 47], whereas, in other studies authors did not
observe any significant difference in the levels in TA subjects
and controls [17, 53]. In an isolated report by Mahajan et al.
MMP-1 levels were found to be insignificant between controls
and TA subjects [17]. Treating TA subjects with prednisolone
resulted in an increase in serum levels of MMP-3 [53, 54],
whereas Matsuyama et al. reported no impact on the MMP-3
levels [46]. The mechanisms by which steroids affect MMP3 serum levels remain unknown; therefore, determining the
MMP-3 level to assess TA disease activity requires more
caution.
Serum levels of MMP-9 were found to be significantly
higher in TA patients as compared to controls [17]. Matsuyama et al. reported significantly augmented levels of
MMP-9 in TA subjects in active phase as compared to
healthy controls. Similar findings were also reported in other
studies [46]. Patients with TA who were in remission had
significantly higher MMP-9 levels than normal controls.
Thus, evaluation of MMP-9 may suggest prior existence of
TA even in inactive patients, although the mechanism of this
elevation is a matter of further investigation. Also, MMP9 was not affected by the prednisolone dose [53]. On the
contrary, Mahajan et al. did not find any significant difference
in the levels of MMP-9 in controls versus patients as well as
active versus in remission TA subjects [17].
In a study reported from Japan, TIMP1 levels were found
to be significantly high in control subjects as compared
to those TA subjects who were in active disease [46]. On
the contrary, a significantly high level of TIMP1 in subjects
with TA as compared to the levels of healthy control subjects was observed in an Indian study cohort [17]. Further,
TIMP1 levels remained statistically higher in TA subjects
in remission when the data was compared with controls.
Higher levels of this endogenous inhibitor of MMPs in TA
subjects in this study were explained as a compensatory or
adaptive phenomenon. Augmented levels of TIMP1 in TA
subjects could be to combat or to compensate and counteract
the deleterious effects caused by increased expression of
MMPs to some extent in TA subjects. Increased levels of
TIMP1 have been observed in patients with coronary artery
disease [51, 55] and in subjects with myocardial infarction
[56].
Currently a number of clinical imaging techniques have
been developed and those are able to correlate with MMP
expression in vascular diseases. In an important study
where outcomes of MRI were analyzed with MMP-9 levels,
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Sun et al. have observed that the serum levels of MMP9 were significantly associated with the severity of lumen
stenosis and wall thickness in TA subjects [47]. Also, these
authors emphasized the fact that MMP-9 has more strong
and significant association with MRI outcome compared to
other markers like ESR and hsCRP, which had a moderate
association [47], suggesting it might be useful to predict
the imaging outcomes of the patients with TA using soluble
markers. Moreover, imaging techniques of MMPs have also
been advanced in the last decade [57, 58]. Such imaging
techniques, if refined in near future, can be used to track the
expression of MMPs in vivo, which will be useful to monitor
both disease progression and therapeutic efficacy.

5. Futuristic Approach and
Concluding Remarks
The management of TA is challenging and includes medical
therapy with steroids, immunosuppressive agents, and revascularization procedure. Despite the large number of studies
with the aim to develop agents that target MMP-TIMP axis,
none have yet been reached to the market for clinical use. The
major caveat is the incomplete understanding of the various
pathways regulating MMP-TIMP axis in vascular diseases.
Moreover, most of the studies assessing this particular axis
in the pathogenesis of vascular disease are extrapolated from
either animal models or majorly in vitro studies, which
may be inaccurate when reached at the door of a clinic.
Minocycline, an inhibitor of MMPs, in combination with
steroids, was reported to induce clinical remission in TA
subjects [59]. Extracellular matrix metalloproteinase inducer
(EMMPRIN), a transmembrane glycoprotein, is capable of
inducing MMPs through direct cell-cell interaction [60];
therefore, strategies that inhibit EMMPRIN expression can
be explored as a promising therapeutic target in future. Of
note, MMP inhibitors developed so far lack specificity and
are associated with number of side effects.
As stated earlier a number of factors (like genetic predisposition, pathogens, and autoimmunity) have been considered to play role in pathophysiology of disease and, therefore,
to assess the disease activity and plan treatment strategy
become difficult. In addition, patients who are in remission
may develop new arterial lesions along follow-up. Therefore,
it has always been a challenge in TA research to assess the disease activity. Also, most of the systemic manifestations are not
specific to vasculitis and moreover vascular feature progresses
very slowly. Undoubtedly, imaging modalities allow earlier
and accurate diagnosis; however, serum biomarkers have
their own advantages over imaging, that is, cost effectiveness,
less cumbersome, and less time to analyze the reports.
Therefore, studies focusing on the association of clinical
imaging techniques with MMP expression in vascular disease
will be the need of this hour. Such studies will allow not only
risk stratification, but also analyzing the effects of any MMPTIMP axis targeted therapy.
The best method to diagnose TA would be one that
involves a multiple biomarker approach rather than a single
biomarker approach. Though some biomarkers show high
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sensitivity or specificity, it should be noted that small-scale
verification in retrospectively selected samples from one
institute might not represent a general test with sample
prospectively collected from multiple institutions. Therefore
the combination of multiple biomarkers that best distinguish
TA samples from controls should be utilized in the development of TA detection technology for clinical applications.
We would like to emphasize that TA has been reported
all over the world, with wide variation in its prevalence in
different geographical areas; therefore, a small sample size
along with a single-center-based is the inherited limitations
for the studies which report such a rare vascular disorder.
Most of the studies reported so far are hypothesis generating
and therefore lack a definitive and firm conclusion. Therefore,
meta-analysis and the multi-institutional studies will be of
importance. Based on the review of literature (as summarized
in Table 1), MMPs and TIMPs cannot be applied for the
routine diagnostic of TA yet and the clinical utility of
these molecules remains to be established. However, there
is evidence that MMPs contribute to the TA pathology and
may be targets for future therapeutic strategies using selective
inhibitors. Therefore, future studies concerning the significance of selected MMPs and their inhibitors, as potential
biomarkers for TA, need to be continued.
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